Please login to the form below

Prosensa Therapeutics

This page shows the latest Prosensa Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Shire rumoured to be pursuing Actelion

Other transactions including rare disease companies of late include Horizon Pharma's $1.1bn deal to buy urea cycle disorder specialist Hyperion Therapeutics and BioMarin $840m purchase of Prosensa in order

Latest news

Alexion boosts rare disease portfolio with $8.4bn Synageva buy

Meanwhile, Horizon Pharma stumped up $1.1bn for urea cycle disorder specialist Hyperion Therapeutics and BioMarin bought Prosensa for $840m, gaining access to its muscular dystrophy drug drisapersen. .
GSK antisense drug fails muscular dystrophy trial

Company and its partner Prosensa suffer setback with drisapersen. GlaxoSmithKline (GSK) and Prosensa suffered a setback when their antisense drug candidate for Duchenne muscular dystrophy (DMD) failed to show efficacy in ... GSK and Prosensa's drug not
First efficacy data for GSK/Prosensa's muscular dystrophy candidate positive

Ups ante in race against Sarepta Therapeutics to market first Duchenne muscular dystrophy drug. ... The positive data on the candidate, called drisapersen, ups the ante in a race between Prosensa/GSK and rival Sarepta Therapeutics to bring the first drug

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

Larry Bell joins Dutch biopharma Prosensa

Takes up role as head of global regulatory affairs. Dutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs. ... For his new role at Prosensa, which focuses on RNA-modulating therapeutics for